Transforming growth factor beta. A biologic chorioretinal glue
W. E. Smiddy, B. M. Glaser, W. R. Green, T. B. Connor Jr, A. B. Roberts, R. Lucas and M. B. Sporn
Bascom Palmer Eye Institute, Miami.
Transforming growth factor beta (TGF-beta) stimulates fibrosis. We studied
its possible role as a bioactive substance for inducing localized
chorioretinal wound healing along the edge of a retinal tear. The TGF-beta
was applied to induced retinal tears that were examined
histopathologically. One day after surgery, neither control nor
TGF-beta-treated eyes developed chorioretinal wound healing. Four days, two
weeks, and two months after surgery, the control eyes still had not
developed chorioretinal wound healing. In contrast, the edges of the
retinal tear treated with TGF-beta were adherent to the underlying Bruch's
membrane via localized fibrous tissue without apparent effects elsewhere.
These results demonstrate intraocular in vivo bioactivity of TGF-beta and
suggest that TGF-beta may have a potential role as an alternative means for
inducing a chorioretinal adhesion in the treatment of retinal tears.
Effect of Smad7 Gene Overexpression on Transforming Growth Factor beta-Induced Retinal Pigment Fibrosis in a Proliferative Vitreoretinopathy Mouse Model
Saika et al.
Arch Ophthalmol 2007;125:647-654.
ABSTRACT
| FULL TEXT
In vivo and in vitro feasibility studies of intraocular use of seprafilm to close retinal breaks in bovine and rabbit eyes.
Sueda et al.
IOVS 2006;47:1142-1148.
ABSTRACT
| FULL TEXT
Transforming Growth Factor-{beta}1, -{beta}2, and -{beta}3 In Vivo: Effects on Normal and Mitomycin C-Modulated Conjunctival Scarring
Cordeiro et al.
IOVS 1999;40:1975-1982.
ABSTRACT
| FULL TEXT
Macular holes---a diagnostic and therapeutic enigma?
KAMPIK
Br. J. Ophthalmol. 1998;82:338-338.
FULL TEXT
Fundus autofluorescence in patients with macular holes imaged with a laser scanning ophthalmoscope
von Rückmann et al.
Br. J. Ophthalmol. 1998;82:346-351.
ABSTRACT
| FULL TEXT
Surgical management of macular holes: results using gas tamponade alone, or in combination with autologous platelet concentrate, or transforming growth factor beta 2
Minihan et al.
Br. J. Ophthalmol. 1997;81:1073-1079.
ABSTRACT
| FULL TEXT